Literature DB >> 9832165

Mice deficient in group IV cytosolic phospholipase A2 are resistant to MPTP neurotoxicity.

P Klivenyi1, M F Beal, R J Ferrante, O A Andreassen, M Wermer, M R Chin, J V Bonventre.   

Abstract

Phospholipase A2 (PLA2) enzymes are critical regulators of prostaglandin and leukotriene synthesis, and they may also play an important role in the generation of intracellular free radicals. The group IV cytosolic form of phospholipase A2 (cPLA2) is regulated by changes in intracellular calcium concentration, and the enzyme preferentially acts to release arachidonic acid esterified at the sn-2 position of phospholipids. We examined the susceptibility of mice carrying a targeted mutation of the cPLA2 gene to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced neurotoxicity. Mutant mice have no functional cPLA2 activity. Mice that were homozygous for the mutation (cPLA2-/-) were significantly resistant to MPTP-induced dopamine depletion as compared with littermate control (cPLA2+/+) and heterozygous mice (cPLA2+/-). These findings provide evidence that cPLA2 plays a role in MPTP neurotoxicity and suggest that cPLA2 may play a role in the development of Parkinson's disease in humans.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9832165     DOI: 10.1046/j.1471-4159.1998.71062634.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  27 in total

Review 1.  Cytosolic phospholipase A₂: physiological function and role in disease.

Authors:  Christina C Leslie
Journal:  J Lipid Res       Date:  2015-04-02       Impact factor: 5.922

2.  Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease.

Authors:  Noemí Fabelo; Virginia Martín; Gabriel Santpere; Raquel Marín; Laia Torrent; Isidre Ferrer; Mario Díaz
Journal:  Mol Med       Date:  2011-06-22       Impact factor: 6.354

Review 3.  The role of secretory phospholipase A₂ in the central nervous system and neurological diseases.

Authors:  Tatsurou Yagami; Yasuhiro Yamamoto; Hiromi Koma
Journal:  Mol Neurobiol       Date:  2013-10-10       Impact factor: 5.590

Review 4.  Phospholipases A2 in ischemic and toxic brain injury.

Authors:  A Sapirstein; J V Bonventre
Journal:  Neurochem Res       Date:  2000-05       Impact factor: 3.996

5.  Phosphatidylinositol transfer protein expression altered by aging and Parkinson disease.

Authors:  Małgorzata Chalimoniuk; Gerry T Snoek; Agata Adamczyk; Andrzej Małecki; Joanna B Strosznajder
Journal:  Cell Mol Neurobiol       Date:  2006-06-16       Impact factor: 5.046

6.  Increased extracellular glutamate evoked by 1-methyl-4-phenylpyridinium [MPP(+)] in the rat striatum is not essential for dopaminergic neurotoxicity and is not derived from released glutathione.

Authors:  S B Foster; H Tang; K E Miller; G Dryhurst
Journal:  Neurotox Res       Date:  2005       Impact factor: 3.911

Review 7.  Low molecular weight phospholipases A2 in mammalian brain and neural cells: roles in functions and dysfunctions.

Authors:  Gianfrancesco Goracci; Monica Ferrini; Vincenza Nardicchi
Journal:  Mol Neurobiol       Date:  2010-03-19       Impact factor: 5.590

8.  Cytosolic phospholipase A2 alpha inhibition prevents neuronal NMDA receptor-stimulated arachidonic acid mobilization and prostaglandin production but not subsequent cell death.

Authors:  Ava L Taylor; Joseph V Bonventre; Tracy F Uliasz; James A Hewett; Sandra J Hewett
Journal:  J Neurochem       Date:  2008-06-28       Impact factor: 5.372

Review 9.  Role of secretory phospholipase a(2) in CNS inflammation: implications in traumatic spinal cord injury.

Authors:  W Lee Titsworth; Nai-Kui Liu; Xiao-Ming Xu
Journal:  CNS Neurol Disord Drug Targets       Date:  2008-06       Impact factor: 4.388

10.  Cytosolic phospholipase A2 alpha amplifies early cyclooxygenase-2 expression, oxidative stress and MAP kinase phosphorylation after cerebral ischemia in mice.

Authors:  Koji Kishimoto; Rung-Chi Li; Jian Zhang; Judith A Klaus; Kathleen K Kibler; Sylvain Doré; Raymond C Koehler; Adam Sapirstein
Journal:  J Neuroinflammation       Date:  2010-07-30       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.